This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Introduction Atrialfibrillation is the most prevalent sustained arrhythmia worldwide and is expected to increase substantially within the coming years. Eligible patients are randomised 1:1 to either a combined supervised and eHealth-based exercise intervention or usual care for 12 months. Trial registration number NCT05164718.
Atrialfibrillation is the most prevalent arrhythmia with a lifetime risk of nearly 30%. It can be associated with reduced quality of life and complications such as heart failure and stroke. Pulmonary vein isolation (PVI) is the most effective treatment for rhythm control.
Data on long-term effects of catheter ablation versus antiarrhythmic drugs (AAD) on health-related quality of life (HRQoL) and atrialfibrillation (AF) burden are limited.
Background Atrialfibrillation (AF) is a major and increasing burden on health services. Resource use in primary and secondary healthcare services, medications and patient-reported quality of life were prospectively collected to estimate differences in costs and quality-adjusted life years (QALYs).
Background We aimed to evaluate the association between atrialfibrillation (AF) burden, duration and number of episodes with healthcare utilisation and quality of life in patients with early paroxysmal AF without a history of AF. Patients were monitored with an insertable cardiac monitor for 1 year. –4.0%).
Atrialfibrillation (AF) is a major global health concern impacting millions and causing symptoms like palpitations, dyspnea, fatigue, dizziness, and chest discomfort. Furthermore, these symptoms reduce patients' quality of life and lead to increased mortality and morbidity.
1 2 Pericardial complications may range from asymptomatic pericardial and/or pleural effusion to cardiac tamponade, and may include PPS, and postoperative atrialfibrillation (POAF), triggered by pericarditis in predisposed individuals.
Atrialfibrillation (AF) significantly affects patients' health-related quality of life (HRQoL), influencing physical, psychological, and social wellbeing.
BackgroundObesity is an important risk factor for atrialfibrillation (AF) development and progression. Furthermore, obesity reduces health-related quality of life (HRQoL), an essential indicator for treatment efficacy of AF ablation.
16, 2025 Primary results from the DEFINE AFib clinical study show the Medtronic LINQ family of insertable cardiac monitors (ICM), paired with a novel algorithm, were able to detect atrialfibrillation episodes and properly risk stratify patients as high risk prior to an AF-related healthcare utilization 80% of the time. 2024, May 15).
Studies estimate that severe regurgitation occurs in up to 4% of individuals 75 and older and is often linked with conditions like heart failure, atrialfibrillation or pulmonary hypertension. We prioritize improving quality of life, particularly for patients experiencing severe fatigue and breathlessness.
Atrialfibrillation (AF) represents the most common cardiac arrhythmia with significant morbidity and mortality implications. It is a common cause of hospital admissions, significantly impacts quality of life, increases morbidity and decreases life expectancy.
Rhythm control therapy and especially atrialfibrillation (AF) ablation are the focus of growing research in patients with AF. Recent findings suggest that reduction of AF burden mediates the beneficial effects of AF ablation on cardiovascular events and quality of life.
Abstract Introduction In hypertrophic cardiomyopathy (HCM), atrialfibrillation (AF) has historically been regarded to have a deleterious impact on clinical course, strongly associated with progressive heart failure (HF) symptoms. Therefore, we evaluated the impact of AF on QoL utilizing patient reported outcome measures (PROMs).
The CEASE-AF trial showed superior effectiveness and similar safety for Hybrid Ablation (HA) vs catheter ablation (CA) to treat non-paroxysmal atrialfibrillation (AF). The resulting impact on quality-of-life (QOL) is unknown.
Objective Atrialfibrillation (AF) ablation services were significantly affected by the COVID-19 pandemic. We aimed to evaluate a symptom-based clinician prioritisation scheme for waiting list management compared with patient-completed quality of life (QoL) scores.
Atrialfibrillation (AF) is the most common heart rhythm disorder in clinical practice. It worsens the quality of life of patients, leads to an increase in the mortality rate because of its association with a high risk of thromboembolic complications.
Background Atrialfibrillation (AF) is common in individuals with heart failure (HF). Individuals with HF and AF may have a reduced functional capacity and quality of life (QoL) which leads to hospital admission and burden on clinical services. Evidence supported the effect of exercise training in individuals with HF.
Atrialfibrillation (AF) is the most common cardiac arrhythmia. Catheter ablation (CA) has emerged as an important modality for managing AF, improving quality of life, and potentially reversing cardiac dysfunction.
A catheter ablation procedure widely used to treat the most common heart rhythm disorder significantly reduces the burden of atrialfibrillation (AF) and results in clinically important improvements in symptoms and quality of life compared with a sham (placebo) procedure, according to late breaking research presented Sept.
BackgroundThe autonomic nervous system (ANS) plays a significant role in atrialfibrillation (AF). The quality of life was assessed by using a dedicated scale [University of Toronto AtrialFibrillation Severity Scale (AFSS)].ResultsThe
Publication date: Available online 29 December 2023 Source: The American Journal of Cardiology Author(s): Lorenzo Braghieri, Arwa Younis, Chadi Tabaja, Pasquale Santangeli, Tyler Taigen, Walid I. Saliba, Oussama M. Wazni, Ayman A.
Catheter ablation of atrialfibrillation (AF) is an established therapy that reduces AF burden, improves quality of life, and reduces the risks of cardiovascular outcomes.
Heart failure with preserved ejection fraction (HFpEF) and atrialfibrillation (AF) have emerged as major age-related epidemics within cardiology. Indeed, these two conditions are commonly found in the same individual, so much so that AF has been used in proposed diagnostic criteria for HFpEF.
Catheter ablation (CA) has become a cornerstone in the management of patients with comorbid atrialfibrillation (AF) and heart failure with reduced ejection fraction (HFrEF). Multiple trials have demonstrated the efficacy of CA with respect to symptom improvement and quality of life in AF patients with HFrEF.
Patients with persistent atrialfibrillation(pers.AF) commonly undergo catheter ablation(CA) for symptom relief and improved quality of life(QoL). However,the benefits of CA compared to DC cardioversion(DCCV) or medical therapy lack substantial evidence from blinded randomized trials.
Catheter ablation (CA) for atrialfibrillation (AF) and heart failure with reduced ejection fraction <40% (HFrEF) is associated with improved outcomes. The patient characteristics, AF effect on quality-of-life questionnaire (AFEQT), and ablation strategies performed remains uncertain in those with and without HFrEF.
Heart failure with preserved ejection fraction (HFpEF) and atrialfibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We
tim.hodson Wed, 03/12/2025 - 15:36 Broward Health recently announced it is now offering the Farapulse Pulsed Field Ablation System to treat atrialfibrillation (A-Fib). This innovative approach not only addresses that need but also improves patient outcomes, ensuring a better quality of life for those diagnosed with A-Fib.
Digoxin has been used in the management of chronic heart failure (HF) and atrialfibrillation (AF) for over 250 years. It is the only drug that combines an inotropic effect with a reduction in ventricular rate in AF. Therefore, in theory it should be an ideal treatment for HF, especially when there is co-existent AF.
Atrialfibrillation (AF), already the most prevalent clinical arrhythmia, is increasing in prevalence1. It is associated with adverse outcomes that significantly impact the quality of life (QoL) experienced by patients. Thus, the accurate evaluation of QoL is an emerging part of the assessment of AF patients2.
Abstract Introduction The prospective, nonrandomized, multicenter Q-FFICIENCY study demonstrated the safety and 12-month efficacy of paroxysmal atrialfibrillation (AF) ablation with the novel QDOT MICRO temperature-controlled, contact force-sensing, radiofrequency (RF) catheter.
ABSTRACT Background Catheter ablation improves symptoms and quality of life in atrialfibrillation patients, but its effect on adverse cardiovascular outcomes and mortality remains uncertain.
Abstract Aim (i) To explore the attitudes of patients with atrialfibrillation (AF) towards oral anti-coagulation (OAC) for stroke prevention post-intracerebral haemorrhage (ICH) and (ii) to explore factors that influence patients decision-making process for stroke prevention. Twelve patients (mean (SD) age 76.2 (6.6)
BACKGROUND:In patients with persistent atrialfibrillation (PersAF), catheter ablation aiming for pulmonary vein isolation (PVI) is associated with moderate clinical effectiveness. The longest atrialfibrillation episode qualifying for PersAF was 28 (10–90) versus 30 (11–90) days.
Objective It is advised that patients engage in physical activity to enhance their quality of life and achieve better results. The purpose of the current study was to measure the efficacy of exercise on the physical ability, cardiac function and cardiopulmonary fitness of patients with AF.
The prevention and treatment of cardiogenic dementia are essential to improve the quality of life, particularly in the elderly and aging population. This study describes the changes in cognitive function associated with coronary artery disease, myocardial infarction, heart failure, atrialfibrillation and heart valve disease.
Tricuspid regurgitation can put added strain on the heart and lead to other cardiovascular issues, which can significantly worsen a person's quality of life, but historically there have been few treatment options," said Lars Søndergaard , M.D.,
Compared with a sham procedure, pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrialfibrillation (AFib) burden at six months, according to results from the SHAM-PVI trial presented at ESC Congress 2024 in London and simultaneously published in JAMA.
Atrialfibrillation (AF) is responsible for significant patient morbidity, and obesity is a major contributor to AF incidence and symptom burden. Final follow-up at six months included clinical and weight data and a quality-of-life questionnaire. Sixty-four patients underwent randomisation.
Aims Direct-acting oral anticoagulants (DOACs) have, to a substantial degree, replaced vitamin K antagonists (VKA) as treatments for stroke prevention in atrialfibrillation (AF) patients. Clinical data, healthcare resource utilisation and EQ-5D-based utilities representing quality of life were collected in yearly follow-ups.
Patients with atrialfibrillation (AF) refractory to rhythm or rate control demonstrate improvement in quality of life, left ventricular ejection fraction (LVEF) and heart failure when treated with atrioventricular junction ablation (AVJA) and His bundle pacing (HBP) or biventricular pacing (BVP).1,2
He was in atrialfibrillation (irregular heart beat) too. Being an active individual even at 90 years, he & his family decided to go for a coronary bypass surgery for a better quality of life. The patient's atrialfibrillation also converted to good normal sinus rhythm after bypass surgery.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content